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Despite the efficacy of IL-12 in cancer experimental models,
clinical trials with systemic recombinant IL-12 showed unac-
ceptable toxicity related to endogenous IFNg production. We
report that systemic administration of a recombinant aden-
ovirus encoding IL-12 (AdCMVmIL-12) has a dramatically
different survival outcome in a number of mouse pure strains
over a wide range of doses. For instance at 2.5 · 109 p.f.u.,
systemic AdCMVmIL-12 killed all C57BL/6 mice but spared
all BALB/c mice. Much higher IFNg concentrations in serum
samples of C57BL/6 than in those from identically treated
BALB/c were found. Causes for heterogeneous toxicity can
be traced to differences among murine strains in the levels
of gene transduction achieved in the liver, as assessed with
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Introduction
Interleukin-12 is a heterodimeric soluble cytokine, which
has shown antitumor activity in murine tumor models1,2
due to its ability to promote cellular immune responses1,3
and to impair tumor vascularization.4,5 IL-12 mediates its
functions through a receptor characterized on T cells and
NK cells,2 but recent functional evidence also shows
effects of IL-12 on dendritic cells and macrophages.6–8
Classical IL-12R consists of two chains (IL-12Rb1 and IL-
12Rb2) which upon stimulation trigger several biochemi-
cal signals with activation of Jak-2, Tyk-2 and subsequent
phosphorylation, dimerization and nuclear translocation
of the transcription factor Stat-4.2 Recently, an alternative
isoform of IL-12Rb2 has been identified on dendritic cells
which activates NF-kB nuclear translocation.6 IL-12 has
been shown to trigger IFNg release not only from T cells
and NK cells,9 but also from macrophages and
dendritic cells.7,8
Both administration of recombinant protein and IL-12
gene transfer approaches with various vectors have suc-
cessfully eradicated experimental malignancies.10–14 Such
encouraging preclinical data prompted testing clinical
safety in a number of cancer patients. After a phase I
clinical trial that established a maximal tolerated dose of
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adenovirus coding for reporter genes. In accordance, IL-12
serum concentrations are higher in susceptible mice. In
addition, sera from C57BL/6 mice treated with AdCMVmIL-
12 showed higher levels of IL-18, a well-known IFNg
inducer. Interestingly, lethal toxicity in C57BL/6 mice was
abolished by administration of blocking anti-IFNg mAbs and
also by simultaneous depletion of T cells, NK cells, and
macrophages. These observations together with the great
dispersion of IFNg produced by human PBMCs upon in vitro
stimulation with IL-12, or infection with recombinant aden-
ovirus encoding IL-12, suggest that patients might also show
heterogeneous degrees of toxicity in response to IL-12 gene
transfer. Gene Therapy (2001) 8, 259–267.
500 ng/kg for i.v. injection of rhIL-12 in an intra-patient
escalation fashion, a phase II trial was started and eventu-
ally stopped because of unacceptable toxicity leading to
two fatalities.15,16 Careful reassessment of patient data
and studies in mouse models led investigators to the con-
clusion that previous low doses of IL-12 in the intra-
patient escalation had desensitized the patients to the
toxic effects of subsequent doses of IL-12.17 Most IL-12
toxicity is related to the production of IFNg, which in
turn activates the overproduction of an array of down-
stream inflammatory mediators.18,19 The IL-12 toxicity
profile in humans frequently involved leukocytopenia
and thrombocytopenia with lower gastrointestinal bleed-
ing and signs of liver dysfunction in some cases.15,17,20
Mice overdosed with IL-12 show alteration in blood
counts, extramedullary hematopoiesis, skeletal and car-
diac muscle necrosis, wasting, splenomegalia and foci of
hepatic necrosis.15,17,18,20 Lung edema, pleural and perito-
neal effusions were also noted. All these effects correlated
with IFNg serum concentrations and all symptoms but
the pulmonary edema were absent in IFNg receptor - /-
mice, indicating a key role for this soluble mediator.20
Indeed, anti-IFNg blocking mAbs abrogated toxicity in
C3H mice overdosed with IL-12.17 IL-18 has been ident-
ified as a potent cofactor of IL-12 to induce IFNg.21,22
IL-12 is instrumental in inducing TH1 immune
responses, enhancing the differentiation of TH0 naive pre-
cursors to produce IFNg.2,23 It has been repeatedly
observed that certain mouse strains such as BALB/c are
prone to mount TH2 responses in contrast to others such
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as C57BL/6 which tend to respond with TH1-biased
responses. This difference accounts for a dramatically
distinct outcome upon infection with a number of intra-
cellular parasites.24
When studying the toxicity of a recombinant adeno-
virus encoding murine IL-12 (AdCMVmIL-12), we noted
that certain mouse strains such as C57BL/6 and DBA/2
were killed by doses of adenovirus which left BALB/c
mice largely unaffected. It was found that toxicity corre-
lated with the serum levels of IFNg. Remarkably different
levels of gene transduction in the liver among murine
pure strains were observed using reporter genes, offering
an explanation for the differences in serum IL-12 and
IFNg. IL-12-induced toxicity, which was completely
inhibited by neutralizing anti-IFNg mAb, was dependent
on T cells, NK cells, and macrophages. In accordance,
parallel genetic or epigenetic variability in humans could
cause idiosyncratic adverse effects in response to IL-12
gene therapy.
Results
Differential susceptibility to similar levels of systemic IL-
12 gene transfer in distinct murine strains
Back-crosses of mice have standardized the genetic back-
grounds of the inbred strains that are routinely used in
the laboratory in order to avoid experimental variability
attributable to genetic differences. Such mice are there-
fore homozygous for the possible alleles in most loci and
display phenotypic characteristics that clearly differen-
tiate them from other pure strains. It was observed that
5 · 109 p.f.u. i.v of AdCMVmIL-12 killed all C57BL/6
mice, but only two out of five BALB/c mice (Figure 1a).
One half of this dose (2.5 · 109 p.f.u.), again killed all
C57BL/6 whereas BALB/c mice were largely unaffected
(Figure 1b). Such a dramatically different outcome was
also observed with 109 p.f.u. (data not shown).
AdCMVmIL-12-injected C57BL/6 mice appeared ill from
day 3 after AdCMVmIL-12 injection. They stopped mov-
ing in the cages, displayed unattended fur and ate poorly.
At day 4, most animals were critically ill with different
degrees of respiratory distress. Such mice had leuko-
penia, thrombocytopenia and showed elevated serum
transaminases (data not shown). No signs of obvious gas-
trointestinal bleeding were found and death occurred
presumably in most cases due to respiratory failure. A
control adenovirus encoding for b-galactosidase
(AdCMVLacZ) did not affect either BALB/c or C57BL/6
mice at the same doses or higher doses at least up to
1010 p.f.u. (data not shown). In contrast, 2.5 · 108 p.f.u.
of AdCMVIL-12 i.v. killed three out of five C57BL/6 mice
and dose dependence was further confirmed since 2.5 ·
107 p.f.u. failed to kill any of 10 thus treated C57BL/6
mice. Serum levels of IFNg were about three times higher
in C57BL/6 mice than in BALB/c mice on days 3 and 5
after i.v treatment with AdCMVIL-12 at 2.5 · 109 p.f.u.
(Figure 1c). Interestingly, when 2 · 106 spleen cells/ml
were cultured in vitro 3 days after AdCMVmIL-12 admin-
istration, C57BL/6 splenocytes released into the culture
supernatants twice as much IFNg as BALB/c spleen cells
(Figure 1d). However, no significant differences in the
amount of IFNg produced by splenocytes from untreated
mice of each strain upon in vitro stimulation with recom-
binant IL-12 could be observed.
In necropsies of moribund C57BL/6 mice upon treat-
ment with 2.5 · 109 p.f.u. of AdCMVmIL-12, the liver
appeared pale and also slightly enlarged. No signs of
hemorrhage within the peritoneal cavity or intestinal
tract were noticed. Lungs appeared clearly congestive.
Microscopic examination of H&E-stained tissue sections
from lung, liver and spleen from identically treated
C57BL/6 and BALB/c disclosed a clear disparity in the
severity of lesions (Figure 2). Livers from C57BL/6 mice
showed a focal necrosis with an intense inflammatory
infiltrate that correlated with increases in serum ALT and
bilirubin (data not shown). C57BL/6 lungs showed an
intense leukocyte infiltration and signs of exudate.
Spleens showed profound disruption of tissue structure
and signs of lymphocyte depletion as previously
reported.25 These lesions were in clear contrast to the
milder pathological changes observed in BALB/c
(Figure 2).
Heterogeneous levels of liver transgene expression after
i.v. injection of recombinant adenovirus
In order to discover reasons for the heterogeneity
observed, we looked at the level of expression of b-
galactosidase in the liver of C57BL/6 and BALB/c mice
i.v.-injected with 2.5 · 109 p.f.u. of AdCMVLacZ. X-gal
histochemical staining data clearly showed that more
cells expressed the transgene in C57BL/6 livers and sug-
gested that the intensity of expression on per cell basis
was also higher than in BALB/c livers (Figure 3a and b).
These data were confirmed when using a similar aden-
ovirus encoding for the enzyme luciferase (AdCMVLuc)
and using chemoluminescence in liver homogenates as
a read out. As shown in Figure 3c, levels of transgene
expression were 10- to 100-fold higher in C57BL/6 livers
than in BALB/c ones. Chemoluminescence was almost
undetectable in homogenates from spleen and lungs
underscoring the liver tropism of adenoviral vectors.
When sera from C57BL/6 mice treated with AdCMVIL-
12 were compared with sera from identically treated
BALB/c mice for the content of IL-12, we also detected
higher levels in C57BL/6, again consistent with a higher
level of gene transduction in this strain (Figure 3d). It is
noteworthy that differences in gene transduction
between strains with reporter genes are greater than
those measured with IL-12 serum concentrations, indicat-
ing the existence of distinct regulatory mechanisms, in
spite of the fact that both genes are under the control of
the same promoter.
A panel of mouse strains show variability in AdCMVmIL-
12-induced toxicity
Apart from the remarkable contrast in the survival out-
come of C57BL/6 mice and BALB/c mice, we analyzed
the effect of 2.5 · 109 p.f.u. of AdCMVmIL-12 in other
genetic backgrounds to look for variability.
The F1 (C57BL/6 · BALB/c) mice were not killed and
remained largely unaffected by AdCMVIL-12 (Figure 4a).
The F1 survival outcomes were equal to BALB/c regard-
less of the gender of parents in the C57BL/6 · BALB/c
crosses thus excluding a purely sex-linked inheritance
trait (data not shown). Consistent with survival data, F1
(C57BL/6 · BALB/c) mice showed IFNg concentrations
as low as those seen in BALB/c mice (Figure 4b). Looking
at the level of gene transduction with AdCMVLuc in the
liver of F1 mice, it was of intermediate levels if compared
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Figure 1 BALB/c and C57BL/6 mice respond differently to gene transfer of IL-12. (a and b) age-matched male BALB/c and C57BL/6 mice were injected
with AdCMVmIL-12 in the tail vein at doses of 5 · 109 p.f.u. (a) and 2.5 · 109 p.f.u. (b). Survival was monitored daily thereafter. (c) Blood samples
were drawn from the orbital plexus on days 3 and 5 after AdCMVmIL-12 i.v. injection. IFNg concentrations were assessed by ELISA and individual
data of a representative experiment out of four performed are shown (statistical comparision was by Mann–Whitney test). (d) IFNg concentration (mean
– s.e.m.) in 24 h supernatants from spleen cell suspensions (1 · 106/ml) derived from four mice per each strain that had been i.v.-treated with 2.5 ·
109 p.f.u. of AdCMVmIL-12 3 days before.
with samples from identically treated BALB/c and
C57BL/6 (not shown).
In DBA/2, i.v. AdCMVmIL-12 induced toxicity that
was as severe as in C57BL/6 mice. In this case, such mice
have a H2 haplotype (H2d) identical to that present in the
BALB/c genome suggesting that the character
susceptibility/lack of susceptibility to AdCMVmIL-12 is
unrelated to this locus. B10.D2 mice also bearing H2d
showed intermediate levels of toxicity with approxi-
mately 40% lethality (three out of seven) and a delay of
several days in the gap from AdCMVmIL-12 injection to
death in comparison with C57BL/6 and DBA/2 (Figure
4a).
Serum IFNg concentrations in DBA/2 mice at day 3
after AdCMVmIL-12 injection were found to reach higher
levels than in identically treated BALB/c, but lower than
in C57BL/6 mice (Figure 4b). Such data suggest that dif-
ferent genetic backgrounds could determine adverse
effects for IL-12 gene therapy. However, differences in
IFNg serum concentrations between B10.D2 and BALB/c
were not found in spite of the different survival out-
comes.
Neutralization of IFNg prevents AdCMVmIL-12 lethal
toxicity as well as simultaneous depletion of CD4+,
CD8+, NK cells and macrophages
Systemic administration of a lethal dose of AdCMVmIL-
12 to C57BL/6 mice was associated with high IFNg pro-
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duction. Repeated i.p. injection of a blocking anti-murine
IFNg mAb protected all mice and resulted in the same
survival as that of identically treated BALB/c mice.
Accordingly, IFNg is critically involved in mechanisms
determining toxicity.
IFNg is mainly secreted by T and NK cells. To study
the role of such cell populations in the lethal effect
observed on C57BL/6 mice, we depleted CD4+, CD8+ and
NK cells both separately or in combination (Figure 5)
with specific antibodies. Although such depletions were
complete upon FACS analysis of peripheral blood mono-
nuclear cells (data not shown), mice succumbed to
AdCMVmIL-12 albeit with some delay if compared with
control mice.
In contrast, depletion of NK cells, CD4+, and CD8+ cells
plus treatment with macrophage-depleting doses of
gadolinium chloride26 fully protected AdCMVmIL-12-
treated C57BL/6 mice from death. Gadolinium treatment
by itself did not protect mice indicating that only simul-
taneous elimination of all such cell populations (T, NK
and macrophages) was protective (Figure 5).
Besides the differential gene transduction levels of IL-
12, we looked for other reasons that could be enhancing
the output of IFNg. IL-18 levels were twice as high in the
sera of C57BL/6 mice treated with AdCMVIL-12 than in
equally treated BALB/c 5 days after adenovirus adminis-
tration (Figure 6). When AdCMVLacZ was used as a con-
trol, no IL-18 levels in sera were detected (not shown).
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Figure 2 Pathological lesions in C57BL/6 in comparison to BALB/c. Rep-
resentative microscopic fields of H&E-stained tissue sections of liver (a, b)
(· 200), spleen (c, d) (· 100), and lung (e, f) ( · 200) from paraffin-embedded
samples obtained from BALB/c (a, c, e) or C57BL/6 (b, d, f) mice 5 days
after i.v. injection of 2.5 · 109 p.f.u. of AdCMVmIL-12.
Since IL-18 is a cofactor for IFNg production known to
contribute in enhancing IL-12 toxicity,21,22 we speculated
that neutralization of IL-18 with specific antibodies
would ameliorate toxicity of AdCMVIL-12 in C57BL/6
mice. However, no delay in the onset of symptoms or
death time-points was observed in spite of the fact that
IL-18 was not detectable in the serum of such animals.
Human subjects show diversity in the IL-12-induced
level of secretion of IFNg from peripheral blood
mononuclear cells
In order to investigate whether human subjects quantitat-
ively differed in the capability of their PBMCs to respond
to IL-12 in terms of in vitro IFNg production, a sample
of healthy volunteers (n = 22) was chosen. PBMCs pur-
ified over Ficoll gradients were exposed to 10 ng/ml of
rhIL-12, and IFNg concentrations released into the super-
natants were determined by ELISA. A great dispersion
was found in the production of IFNg (CV = 90%) with a
range from 150 pg/ml to 13000 pg/ml (Figure 7a).
We could not assess the level of infection by adeno-
virus in human liver cells from different subjects but our
data suggest that other features could account for differ-
ential susceptibility to IL-12-mediated adverse effects in
humans. We also infected in vitro PBMCs of 16 donors
with an adenovirus encoding human IL-12 (AdCMVhIL-
12) and again great dispersion was observed in the out-
put of IFNg into the supernatants (Figure 7b). Variability
of infection on per cell basis was difficult to assess since
recombinant adenovirus only infected a small proportion
(less than 5%) of PBMC, mainly among the adherent
population. A good correlation was found in the level of
IFNg induced by rIL-12 and AdCMVhIL-12, indicating
that the main factor of variability in humans was the
response to IL-12. It should be noted that PBMC secreted
detectable levels of IFNg in six of 12 cases also in
response to AdCMVLacZ (not shown), probably
reflecting previous contact of the subjects with adeno-
viral antigens, thus adding another potential factor for
individual variability.
As a whole these data suggest that several factors
could account for individual variability among humans
in IFNg production in response to IL-12 gene therapy,
giving rise to a spectrum of differential toxicity.
Discussion
In this study we describe differential susceptibility to sys-
temic gene transfer of IL-12 in various mouse strains
which can be accounted for by quantitative variations in
IFNg production. At least for C57BL/6 and BALB/c, the
difference seems to be related to a differential level of
gene transduction in liver cells by identical doses of first
generation recombinant adenovirus. Reasons for differen-
tial level of transduction could involve several steps in
the process, from viral entry to gene expression. No dif-
ference in surface MHC class I or avb3 were found by
flow cytometry on the surface of hepatocyte cell suspen-
sions from C57BL/6 and BALB/c. These proteins are
known to be involved in virus attachment and internaliz-
ation.27 We are trying to explore a possible differential
expression of CAR (Coxackie adenovirus receptor) but no
reliable mAbs against mouse CAR are yet available. It
should be stressed that differential gene transduction
might not be the only mechanism involved in differential
susceptibility, and accordingly, we detect more intense
differences in transduction levels of luciferase than in
serum levels of IL-12 suggesting that compensatory
mechanisms have been elicited in the case of IL-12.
Data with gene transduction of luciferase in F1
(BALB/C · C57BL/6) livers show that gene transduction
levels are intermediate to those in the parental strains.
The genetic trait for this character is currently being
explored with analysis of the F2 generation attempting
to find the gene or genes involved. Interestingly, IFNg in
sera from F1 mice treated with AdCMVIL-12 is similar
to that in sera from BALB/c, again indicating that other
mechanisms of regulation beyond gene transduction exist
in the case of the cytokines.
IL-12 has proved to be a major hope in the fight against
cancer.1 Both treatment with purified protein and gene
transfer with recombinant vectors have displayed unpre-
cedented success in murine experimental tumors. Recent
data in cutaneous lymphoma patients undergoing sys-
temic or intralesional injection of rhIL-12 have also been
extremely encouraging.28 Our group as well as others is
about to start clinical trials in cancer patients based on
intratumoral injection of IL-12 encoding adenoviruses.
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Figure 3 Murine strain-related differences in liver gene transduction levels by recombinant adenovirus. (a and b) X-gal staining of liver sections from
C57BL/6 and BALB/c mice treated with 2.5 · 109 p.f.u. of AdCMVLacZ (· 100). (c) Relative light units per mg of total protein in liver homogenates
from BALB/c and C57BL/6 mice treated with two doses of AdCMVLuc. Data represent individual mice from a representative experiment. Statistical
comparison was by Mann–Whitney test. (d) IL-12 serum concentrations in sera of C57BL/6 o BALB/c mice 3 days after i.v. injection of AdCMVIL-
12 (statistical comparison was by Mann–Whitney test).
Figure 4 Strain-related differential survival of mice treated with AdCMVmIL-12. Male age-matched mice from the indicated strains were injected with
2.5 · 109 p.f.u. of AdCMVmIL-12 i.v. Survival was monitored daily thereafter (a) and IFNg concentrations were determined in serum samples pooled
from five mice at day 3 after AdCMVIL-12 injection (b). Data are representative of two independent experiments.
Although confinement of IL-12 to the lesion should
clearly downsize the systemic adverse effects, there is
much interest in the assessment of potential risks and
adverse reactions.
Previous differential toxicity to IL-12 among mouse
strains has been found in a model of glomerulonephritis
and genetic background-related differences in the spec-
trum of IL-12-induced lesions had been noted pre-
viously.29 We report a dramatic difference in survival
over a wide range of doses. Importantly, we have found
that in vivo depletion of CD4+, CD8+ asialoGM-1+ and
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gadolinium-sensitive cells was required to achieve the
same level of protection as that observed when blocking
with anti-IFNg antibodies. Both CD4 and CD8 T cells and
NK cells are known to be major sources of IFNg. In fact,
a crucial role of NK cells in a toxic shock model induced
by combined administration of IL-2 and IL-12 has been
demonstrated.30 Curiously, IFNg was not neccessary in
that system since toxicity occurred in IFNg receptor- /-
mice.30
The role of macrophages shown in mice treated with
gadolinium is difficult to assess. On one hand, they are
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Figure 5 Simultaneous depletion of T cells, NK cells and macrophages or
in vivo neutralization of IFNg protects C57BL/6 mice from AdCMVmIL-
12 toxicity. Mice i.p. treated with the indicated antibodies and/or i.v with
10 mg/kg of gadolinium chloride during the 3 days before AdCMVmIL-
12 i.v. injection (2.5 · 109 p.f.u. per mouse) and weekly thereafter as
described in Materials and methods, were monitored for survival.
Depletion was monitored by FACS analysis of peripheral blood mono-
nuclear cells in identically treated selected mice (data not shown). Data
are representative of two independent experiments.
Figure 6 Different IL-18 serum concentrations in C57BL/6 and BALB/c
mice treated with AdCMVmIL-12. Serum concentrations of IL-18 (mean
– s.e.m.) determined by ELISA in BALB/c or C57BL/6 5 days after i.v.
injection of 2.5 · 109 p.f.u. of AdCMVmIL-12.
potential sources of IFNg as recently reported,7 and on
the other hand, they can secrete many downstream
inflammatory mediators in response to IFNg.31 Recent
information also suggests a major role for lymphoid den-
dritic cells as a source of IFNg.8 It should be noted that
depletions with anti-CD8a mAbs also deplete a subset of
this cell type.8 We have found interesting differences in
the levels of serum IL-18 among susceptible and non-sus-
ceptible mouse strains. IL-18 is a potent promoter of
IFNg32 production that synergizes with IL-1222 but we
could not inhibit toxicity with anti-IL-18 neutralizing
antibodies. Thus, although IL-18 could be involved in the
differential toxicity observed, its role does not appear to
be critical.
Although highly expressed in macrophages, iNOS
(inducible nitric oxide synthetase) activity is not an absol-
ute requirement for IL-12 toxicity since C57BL/6 mice
treated with the NOS inhibitor L-NAME also succumb to
IL-12 gene transfer as well as iNOS- /- mice (data not
shown). None the less, iNOS activity has been found to
be instrumental for the immunosupression observed after
overdosing IL-12.25,33
We present data that suggest human individual varia-
bility in the response to IL-12 gene transfer. Although our
data are preliminary, this issue is important when con-
sidering clinical development of such adenoviruses. It is
of note that our AdCMVhIL-12 has been tested in
non-human primates and that serious toxicity was found
only after injection of very high systemic doses of the
recombinant adenovirus (Sangro et al, manuscript in
preparation). Our plans for the clinic only involve intra-
tumoral injection which has shown remarkable efficacy
and safety profiles in mouse tumor models probably
related, as mentioned above, to confinement of high con-
centrations of IL-12 to the local tumor environment only.
However, it is noteworthy that even under those con-
ditions some viral vector reaches systemic circulation and
infects liver cells.34 Our data with human PBMCs uncover
at least two possible sources of polymorphism in the
response to IL-12 gene therapy in humans: (1) differential
infectability of liver cells likewise among murine strains,
(2) variable sensitivity to IL-12 in IFNg-secreting cells. In
vitro laboratory tests assessing IFNg secretion from
PBMCs in response to rhIL-12 or AdCMVhIL-12 might
correlate with different clinical outcomes or adverse reac-
tions. As a whole, our results indicate that individual
variability might cause shifts in the dose/response curve
for IL-12 gene therapy and such information would be
important for clinical development.
Materials and methods
Construction of adenovirus
Recombinant adenovirus carrying murine IL-12
(AdCMVmIL-12) has been previously reported.35 Briefly,
an expression cassette of IL-12 under the control of the
CMV promoter was constructed encompassing IL-12 p35
cDNA, an internal ribosomal entry site (IRES), IL-12 p40
cDNA and a polyadenylation signal. Recombinant aden-
ovirus encoding the IL-12 cassette of expression was
generated by cotransfection of 293 cells according to
standard procedures.36 Adenovirus carrying lacZ
(AdCMVLacZ) or luciferase reporter genes (AdCMVLuc,
a kind gift from Dr David Brenner, University of North
Carolina, Chapel Hill, NC, USA) under the control of the
CMV promoter were produced similarly. Recombinant
adenoviruses were isolated from a single plaque,
expanded in 293 cells, and purified by double cesium
chloride ultracentrifugation. Purified virus was exten-
sively dialyzed against 10 mm Tris 1 mm MgCl2 and
stored in aliquots at - 80° C and was carefully titrated by
plaque assay.36 The adenovirus encoding the genes of
human IL-12 (AdCMVhIL-12) will be described else-
where (C Qian et al, manuscript in preparation).
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Figure 7 Individual differences among human PBMCs to produce IFNg in vitro in response to IL-12. PBMC obtained from healthy volunteers were
plated at 2 · 106 cells/ml and stimulated with 10 ng/ml of human rIL-12 (a) or by in vitro infection with AdCMVhIL-12 at MOI of 100 (b). Supernatants
collected 48 h (a) or 72 h (b) later were analyzed by ELISA to determine IFNg concentrations. The small upper panel displays the correlation of IFNg
concentrations induced by rIL-12 and AdCMVhIL-12 in cases when both samples were available. Pearson’s correlation coefficient was used for statistical
analysis (CV, coefficient of variation (%)).
Animals, cell culture and reagents
Five- to eight-week-old male BALB/c (H2d), C57BL/6
(H2b), F1 (BALB/c · C57BL/6), B10.D2 (H2d) and DBA/2
(H2d) mice were purchased from Harlan (Barcelona,
Spain) and were housed according to institutional guide-
lines. The 293 cells were maintained in DMEM medium
supplemented with 10% heat-inactivated fetal calf serum
(FCS), 2 mm l-glutamine, 100 U/ml streptomycin, 100
mg/ml penicillin. All cell culture reagents were from
GIBCO (Basel, Switzerland).
Peripheral blood was obtained from healthy volunteers
donors. Fresh peripheral blood mononuclear cells
(PBMC) were separated by Ficoll–Hypaque density
gradient centrifugation (Vacutainer; Becton Dickinson,
Madrid, Spain) and cultured in RPMI 1640 medium with
100 U/ml streptomycin, 100 mg/ml penicillin, 10 mg/ml
ciprofloxacin, and supplemented with 10% FCS. Recom-
binant hIL-12 and mIL-12 were obtained from Peprotech
(London, UK).
Animal studies
Mice in groups of five to seven received a single i.v. injec-
tion of AdCMVmIL-12 at different doses on day 0. In
some cases mice received i.p. administration of mAbs or
i.v. gadolinium chloride. Mice were carefully observed
for signs of toxicity and followed daily for survival. In
some cases mice receiving AdCMVLuc were killed and
their livers removed for generation of tissue homogenates.
Serum levels of IFNg, IL-12 and IL-18
Mouse and human IFNg concentrations (Endogen, Wob-
urn, MA, USA), IL-12 (Pharmingen, San Diego, CA, USA)
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and IL-18 (R&D Systems, Abingdon, UK) were assessed
by enzyme-linked immunoabsorbent sandwich assay
(ELISA) according to the manufacturer’s instructions.
Mouse blood samples were drawn from the retro-
orbital sinus. Red cell-depleted splenocytes in RPMI 1640
10% FCS for 24 h and tissue culture supernatants were
proccessed. Human peripheral mononuclear cells were
obtained by Ficoll gradient centrifugation from healthy
volunteers.
Luciferase assays on mouse livers
Mice were killed at day 3 after systemic AdLuc adminis-
tration. Livers were harvested and stored at - 80° C. After
thawing, 1.5 ml of Reporter Lysis Buffer (Promega, Madi-
son, WI, USA) was added to each liver specimen. Liver
tissues were homogenized using Ultraturrax (Ika-Werke,
Staufen, Germany) at room temperature, and cell debris
was removed by two sequencial high speed centrifuga-
tions. Twenty ml of cell-free extracts were added to 100
ml of luciferase assay reagent (Luciferase Assay System;
Promega). Relative light units (RLU) were determined
using EG&G Berthold Luminometer (Aliquippa, PA,
USA). Total amount of liver protein was determined by
the BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
X-gal staining
AdCMVLacZ (2.5 · 109 p.f.u.) in 150 ml of saline was
injected intravenously into C57BL/6 and BALB/c mice.
Animals were killed 3 days later, and the livers were
excised, immediately embedded in optimal cutting tem-
pereture compound (OCT; Tissue Tek, Zoeterwoude, The
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Netherlands) and frozen in liquid nitrogen. Sections of 6-
mm thickness were fixed with glutaraldehyde (0.5%) and
stained with 5-bromo-4-chloro-3-indolyl-b-galactosidase
as described previously.37
Depletion of lymphocytes, NK cells and macrophages
L3T4 (CD4+)-specific rat anti-mouse hybridoma GK1–5
and (CD8+)-specific rat anti-mouse hybridoma H35.17.2
were used to obtain anti-CD4+ and anti-CD8+ antibodies
(ATCC, Rockville, MD, USA). Ascitic fluid was obtained
from pristane-primed nude mice injected with 106
hybridoma cells. Mice, four to five in each group, were
depleted of CD4+ or CD8+ cells by intra-peritoneal injec-
tion of 100 ml of anti-CD4+ or anti-CD8+ antibodies five
times, on days - 3, - 2, - 1, 7 and 14. Animals received an
i.v. injection of AdCMVmIL-12 on day 0. Depletion of NK
cells was accomplished via i.v. (100 ml per dose) adminis-
tration of a rabbit anti-AsialoGM1 antiserum (Wako,
Neuss, Germany) on day - 2, - 1, before AdCMVmIL-12
administration and every 7 days thereafter.38 Anti-IFNg
mAb (R4–6A2; ATCC) was given i.p. as ascitis fluid (100
ml per dose) starting on days - 2, - 1 and every 3 days
thereafter. Mice were depleted of monocytes/
macrophages by i.v. injection of 10 mg/kg per dose gado-
linium chloride (Aldrich, Milwaukee, WI, USA) 36 and 3
h before AdCMVmIL-12 injection and every 2 days there-
after.
Pathological studies
Animals were killed 5 days after AdCMVmIL-12 therapy.
Liver, spleen and lung were collected, fixed in 10% buff-
ered formalin, sectioned and stained with hematoxylin
and eosin (H&E) for histopathological analysis. Blood
counts, serum aminotransferases and creatinine were
measured by standard clinical laboratory techniques.
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